<<Doc2.doc>>
This is by no means a political statement.
Recently, while compiling a legislative history of PL 110-85:
the Federal Food, Drug, and Cosmetic Act to revise and extend the
user-fee programs for prescription drugs and for medical devices, to
enhance the postmarket authorities of the Food and Drug Administration
with respect to the safety of drugs, and for other purposes
I came to understand that very little in the way of mark up was done.
The attached article sums up the situation and perhaps sheds some light
on the similar circumstances for other legislation.
Thomas does a history "light" on this bill (HR 2900 then HR3580). CQ
(cq.com), a fee-based service, lends itself to much greater detail and,
I believe, does allow one to set up email alerts on legislation.
Just my 2 cents worth downwind (again not a political but rather an
atmospheric statement) from the Nation's Capitol in the Nation's
Capital.
Cheers!
___________________________________
Tottie Degaitas
Senior Research Specialist
King & Spalding LLP
1700 Pennsylvania Ave.
Washington, DC 20006
tdegaitas@kslaw.com
202.661.7979
FAX 202.626.3737
Confidentiality Notice
This message is being sent by or on behalf of a lawyer. It
is intended exclusively for the individual or entity to
which it is addressed. This communication may contain
information that is proprietary, privileged or confidential
or otherwise legally exempt from disclosure. If you are
not the named addressee, you are not authorized to read,
print, retain, copy or disseminate this message or any part
of it. If you have received this message in error, please
notify the sender immediately by e-mail and delete all
copies of the message.
This archive was generated by hypermail 2b29 : Mon Dec 03 2007 - 09:57:05 PST